Publication | Open Access

Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor

Persistent RiskTransplantationMarrow TransplantationStem Cell TransplantationImmunologyHematologyHepatitisHbv ReactivationGraft SurvivalBlood TransplantationMedicineCell TransplantationExtensive Lamivudine Prophylaxis